Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Yusuf Menda
Modality
radiopharmaceutical
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05557708CT.gov A Safety Study of 212Pb-Pentixather Radioligand Therapy | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Carcinoid Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 212-lead pentixather (this asset) | Yusuf Menda | Early P1 | C · 39 |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BB |
| Pazopanib | National Cancer Institute (NCI) | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Romidepsin | National Cancer Institute (NCI) | P2 | CCC |
| Edotreotide | British Columbia Cancer Agency | P2 | CCC |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Roswell Park Cancer Institute | P1 | CCC |
| Cixutumumab | National Cancer Institute (NCI) | P1 | CC |
| Everolimus | National Cancer Institute (NCI) | P1 | CC |
+8 more in the Lung Carcinoid Tumor cohort
Other indications for 212-lead pentixather
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Neuroendocrine Neoplasm | — | Early P1 | C · 39 |
| Small Cell Lung Carcinoma | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 212-lead pentixather in Lung Carcinoid Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/212-lead-pentixather-lung-carcinoid-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →